With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support today during our fall member drive.
Cedars-Sinai Sees Early Promise In COVID-19 Treatment Study
A vial of the drug Remdesivir presented this week at a news conference in Germany announcing the start of a trial there. (Ulrich Perrey / AFP via Getty Images)
()
A small trial of an experimental antiviral drug that could treat COVID-19 patients has shown encouraging results, Cedars-Sinai Hospital officials said today.
Cedars-Sinai is among dozens of sites around the world participating in a clinical trial of the drug Remdesivir. A study about what's happened so far was published Friday in the New England Journal of Medicine.
Cedars-Sinai's director of epidemiology says definitive conclusions cannot be drawn, but results from this group of patients are hopeful.
Keep in mind the sample size is very small. There was also no control group receiving a placebo, a common practice in clinical trials.
Support for LAist comes from
According to the study, 61 patients received at least one dose of the drug but only 53 were able to be analyzed. Of those, 22 were in the U.S.
The study found 18 days after the initial dose:
- 36 patients (68%) improved, including 17 of the 30 patients who were receiving mechanical ventilation who were extubated.
- 25 patients (47%) were discharged
- 7 patients (13%) died
Of the sickest patients, those receiving "invasive ventilation" the mortality rate was 18% (6 of 34). There was also one death of a patient not receiving invasive ventilation. The study's authors also reported side effects ranging from a rash and diarrhea to acute kidney injury.
Our news is free on LAist. To make sure you get our coverage: Sign up for our daily coronavirus newsletter. To support our non-profit public service journalism: Donate Now.
MORE ON CORONAVIRUS:
At LAist, we believe in journalism without censorship and the right of a free press to speak truth to those in power. Our hard-hitting watchdog reporting on local government, climate, and the ongoing housing and homelessness crisis is trustworthy, independent and freely accessible to everyone thanks to the support of readers like you.
But the game has changed: Congress voted to eliminate funding for public media across the country. Here at LAist that means a loss of $1.7 million in our budget every year. We want to assure you that despite growing threats to free press and free speech, LAist will remain a voice you know and trust. Speaking frankly, the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news in our community.
We’re asking you to stand up for independent reporting that will not be silenced. With more individuals like you supporting this public service, we can continue to provide essential coverage for Southern Californians that you can’t find anywhere else. Become a monthly member today to help sustain this mission.
Thank you for your generous support and belief in the value of independent news.
Chip in now to fund your local journalism
(
LAist
)
Trending on LAist
-
Metro officials said it will be able to announce an opening date “soon.” -
While working for the county, the DA’s office alleges that 13 employees fraudulently filed for unemployment, claiming to earn less than $600 a week. -
The L.A. County Board of Supervisors on Tuesday voted to declare immigration enforcement actions a local emergency. -
Tens of thousands of workers across Southern California walk out over pay and staffing issues. -
People in and around recent burn scars should be alert to the risk of debris flows. Typical October weather will be back later this week. -
Jet Propulsion Laboratory leadership says the cuts amount to 11% of the workforce.
Best of LAist